ACB

Aurora Cannabis Inc.

Aurora Cannabis Inc. (ACB) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Growth (C-). The rating has held at C+ for 8 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
B+
Factor Score 3.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -41.9
EV / EBITDA -7.4
Rev Growth YoY -8.8%
Gross Margin 44.2%
Price Return 3M 25.6%
Price Return 12M 5.0%
Catalyst Signal 0.00
Market Cap $303.1M
TTM Revenue $314.1M
Price / Sales 1.0
ROE -9.4%

Historical Factor Score Progression

Held C+ for 8 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B- (3.0) C- (1.9) C+ (2.8) B+ (3.6) C+ (2.6) C+ (2.8)
2026-11-10 B- (3.0) C- (1.9) C+ (2.8) A- (3.9) C+ (2.6) C+ (2.8)
2026-11-03 B- (3.0) C- (1.9) C+ (2.8) B (3.5) C+ (2.7) C+ (2.8)
2026-10-27 B- (3.0) C- (1.9) B- (2.9) B (3.4) C+ (2.6) C+ (2.8)
2026-10-20 B- (3.0) C- (1.9) C+ (2.8) B- (3.1) C+ (2.6) C+ (2.7)
Page 1 of 4